CYP2D6 Testing and Postoperative Opioids

Investigators evaluate whether genotype-guided prescribing improves postoperative pain management.

1

CYP2D6 genotype-guided opioid prescribing improved concordance with metabolic phenotype but did not affect pain intensity or opioid use post-surgery.
2

In a trial with 1,602 patients, genotype-guided prescribing led to significant changes in opioid selection but similar pain outcomes compared to usual care.
3

The intervention group had 64% concordance in opioid prescribing, while only 27% of the control group matched opioids to metabolic phenotype.
4

Despite differences in prescribed opioids, pain and opioid use were similar between genotype-guided and control groups at 10 days post-surgery.
5

The study concluded that CYP2D6-guided opioid therapy does not enhance pain management in the context of multimodal postoperative care.

1